Behnam Tajik, Ari Voutilainen, Jussi Kauhanen, Moshen Mazidi, Gregory Y. H. Lip, Tomi-Pekka Tuomainen, Masoud Isanejad
{"title":"男性的脂质状况、脂质比率、载脂蛋白和心脏代谢多发性疾病的风险:Kuopio缺血性心脏病风险因素研究。","authors":"Behnam Tajik, Ari Voutilainen, Jussi Kauhanen, Moshen Mazidi, Gregory Y. H. Lip, Tomi-Pekka Tuomainen, Masoud Isanejad","doi":"10.1002/lipd.12337","DOIUrl":null,"url":null,"abstract":"<p>The blood level of lipids, apolipoproteins, and lipid ratios are important predictors of some chronic diseases. However, their association with cardiometabolic multimorbidity (CMM) is less known. We evaluated a wide range of lipid profiles and lipid ratios, including low-density lipoprotein-cholesterol (LDL-C), very-low-density lipoprotein-cholesterol (VLDL-C), high-density lipoprotein-cholesterol (HDL-C), and apoA1 and B, as well triglyceride and total cholesterol with risk of incident CMM. In 1728 men aged 52.5 ± 5.2 years from the Kuopio Ischaemic Heart Disease were included in this study. We defined CMM as coexisting of two or more of stroke, type 2 diabetes mellitus (T2D), coronary heart disease (CHD). A Cox proportional hazard regression method was applied to evaluate the risk of CMM against the exposures. During the mean follow-up of 22.4 years, 335 men suffered from CMM conditions. Higher serum triglyceride and VLDL concentrations were associated with a higher risk of coexisting T2D-CHD (HRs 1.99 (95% CI, 1.12–3.53) and HRs 1.79 (95% CI, 1.04–3.11), respectively. Whereas higher HDL was associated with lower incident [HRs 0.49 (95% CI, 0.40–1.00)]. The HRs for coexisting T2D-CHD was 2.02 (95% CI, 1.01–3.07) for total cholesterol/HDL-C, 1.85 (95% CI, 1.04–3.29) for triglyceride/HDL-C, 1.69 (95% CI, 1.01–2.31) for Non-HDL-C/HDL-C, and 1.89 (95% CI, 1.03–2.46) for apoB/apoA1. In contrast, serum LDL-C/apoB ratios were inversely associated with the risk of coexisting T2D-CHD [HRs 0.50 (95% CI, 0.28–0.90)]. No associations were observed between our exposures and other CMM conditions. In conclusion, elevated triglyceride, VLDL-C, total cholesterol/HDL-C, TG/HDL-C, apoB/apoA1 as well as lower LDL-C/apoB were independently associated with the higher risk of T2D-CHD coexistence.</p>","PeriodicalId":18086,"journal":{"name":"Lipids","volume":"57 2","pages":"141-149"},"PeriodicalIF":1.8000,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305561/pdf/","citationCount":"5","resultStr":"{\"title\":\"Lipid profile, lipid ratios, apolipoproteins, and risk of cardiometabolic multimorbidity in men: The Kuopio Ischaemic Heart Disease Risk Factor Study\",\"authors\":\"Behnam Tajik, Ari Voutilainen, Jussi Kauhanen, Moshen Mazidi, Gregory Y. H. Lip, Tomi-Pekka Tuomainen, Masoud Isanejad\",\"doi\":\"10.1002/lipd.12337\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The blood level of lipids, apolipoproteins, and lipid ratios are important predictors of some chronic diseases. However, their association with cardiometabolic multimorbidity (CMM) is less known. We evaluated a wide range of lipid profiles and lipid ratios, including low-density lipoprotein-cholesterol (LDL-C), very-low-density lipoprotein-cholesterol (VLDL-C), high-density lipoprotein-cholesterol (HDL-C), and apoA1 and B, as well triglyceride and total cholesterol with risk of incident CMM. In 1728 men aged 52.5 ± 5.2 years from the Kuopio Ischaemic Heart Disease were included in this study. We defined CMM as coexisting of two or more of stroke, type 2 diabetes mellitus (T2D), coronary heart disease (CHD). A Cox proportional hazard regression method was applied to evaluate the risk of CMM against the exposures. During the mean follow-up of 22.4 years, 335 men suffered from CMM conditions. Higher serum triglyceride and VLDL concentrations were associated with a higher risk of coexisting T2D-CHD (HRs 1.99 (95% CI, 1.12–3.53) and HRs 1.79 (95% CI, 1.04–3.11), respectively. Whereas higher HDL was associated with lower incident [HRs 0.49 (95% CI, 0.40–1.00)]. The HRs for coexisting T2D-CHD was 2.02 (95% CI, 1.01–3.07) for total cholesterol/HDL-C, 1.85 (95% CI, 1.04–3.29) for triglyceride/HDL-C, 1.69 (95% CI, 1.01–2.31) for Non-HDL-C/HDL-C, and 1.89 (95% CI, 1.03–2.46) for apoB/apoA1. In contrast, serum LDL-C/apoB ratios were inversely associated with the risk of coexisting T2D-CHD [HRs 0.50 (95% CI, 0.28–0.90)]. No associations were observed between our exposures and other CMM conditions. In conclusion, elevated triglyceride, VLDL-C, total cholesterol/HDL-C, TG/HDL-C, apoB/apoA1 as well as lower LDL-C/apoB were independently associated with the higher risk of T2D-CHD coexistence.</p>\",\"PeriodicalId\":18086,\"journal\":{\"name\":\"Lipids\",\"volume\":\"57 2\",\"pages\":\"141-149\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305561/pdf/\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lipids\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/lipd.12337\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lipids","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lipd.12337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Lipid profile, lipid ratios, apolipoproteins, and risk of cardiometabolic multimorbidity in men: The Kuopio Ischaemic Heart Disease Risk Factor Study
The blood level of lipids, apolipoproteins, and lipid ratios are important predictors of some chronic diseases. However, their association with cardiometabolic multimorbidity (CMM) is less known. We evaluated a wide range of lipid profiles and lipid ratios, including low-density lipoprotein-cholesterol (LDL-C), very-low-density lipoprotein-cholesterol (VLDL-C), high-density lipoprotein-cholesterol (HDL-C), and apoA1 and B, as well triglyceride and total cholesterol with risk of incident CMM. In 1728 men aged 52.5 ± 5.2 years from the Kuopio Ischaemic Heart Disease were included in this study. We defined CMM as coexisting of two or more of stroke, type 2 diabetes mellitus (T2D), coronary heart disease (CHD). A Cox proportional hazard regression method was applied to evaluate the risk of CMM against the exposures. During the mean follow-up of 22.4 years, 335 men suffered from CMM conditions. Higher serum triglyceride and VLDL concentrations were associated with a higher risk of coexisting T2D-CHD (HRs 1.99 (95% CI, 1.12–3.53) and HRs 1.79 (95% CI, 1.04–3.11), respectively. Whereas higher HDL was associated with lower incident [HRs 0.49 (95% CI, 0.40–1.00)]. The HRs for coexisting T2D-CHD was 2.02 (95% CI, 1.01–3.07) for total cholesterol/HDL-C, 1.85 (95% CI, 1.04–3.29) for triglyceride/HDL-C, 1.69 (95% CI, 1.01–2.31) for Non-HDL-C/HDL-C, and 1.89 (95% CI, 1.03–2.46) for apoB/apoA1. In contrast, serum LDL-C/apoB ratios were inversely associated with the risk of coexisting T2D-CHD [HRs 0.50 (95% CI, 0.28–0.90)]. No associations were observed between our exposures and other CMM conditions. In conclusion, elevated triglyceride, VLDL-C, total cholesterol/HDL-C, TG/HDL-C, apoB/apoA1 as well as lower LDL-C/apoB were independently associated with the higher risk of T2D-CHD coexistence.
期刊介绍:
Lipids is a journal of the American Oil Chemists'' Society (AOCS) that focuses on publishing high-quality peer-reviewed papers and invited reviews in the general area of lipid research, including chemistry, biochemistry, clinical nutrition, and metabolism. In addition, Lipids publishes papers establishing novel methods for addressing research questions in the field of lipid research.